共查询到20条相似文献,搜索用时 15 毫秒
1.
2.
生长激素(growth hormone,GH)是调控人生长发育和新陈代谢的重要物质,广泛地参与各种代谢.大量研究表明,重组人生长激素(recombinant human growth hormone,rhGH)在增强蛋白质合成代谢、促进免疫功能恢复、加速创口愈合及减少并发症等方面有重要临床意义,已经应用治疗包括青少年矮小症、先天性卵巢发育不全综合征、慢性肾脏病、充血性心力衰竭、慢性阻塞性肺病、重症急性胰腺炎、严重烧伤等多种疾病.随着生物医学技术的发展,人们也尝试利用rhGH治疗某些荷瘤患者与肿瘤术后患者,但GH能否刺激肿瘤细胞生长、增加肿瘤细胞侵袭转移的潜能已引起临床注意. 相似文献
3.
《中华骨质疏松和骨矿盐疾病杂志》2019,(6)
通过临床检查、生化指标检测、全外显子组检测及遗传分析,确诊1例假假性甲状旁腺功能减退症(pseudo-pseudohypoparathyroidism,PPHP)患儿。在不违背生长激素治疗禁忌证的情况下,每日皮下注射基因重组人生长激素(recombinant human growth hormone,rhGH)粉剂6 IU,治疗时间持续7个月。治疗开始4个月患儿身高增长4.3 cm,治疗7个月身高总共增长6.7 cm。治疗过程中监测血糖、血脂、胰岛素、胰岛素样生长因子-1、甲状腺功能、电解质8项(包括钙磷)、25羟维生素D及雌激素、雄激素均没有明显异常。可见,rhGH不仅对生长激素缺乏的矮小患者有效,对本例PPHP矮小患儿的身高增长也有效。 相似文献
4.
目的 探讨单纯性生长激素缺乏症(isolated growth hormone deficiency,IGHD)以及特发性矮小症(idiopathic short stature,ISS)患儿经重组人生长激素(recombinant human growth hormone,rhGH)治疗后,血清C型利钠肽氨基末端(NTproCNP)浓度的变化及其与生长速率(growth velocity,GV)的关系.方法 共有48例青春期前的患儿纳入研究(IGHD 25例,ISS 23例),并给予rhGH治疗1年.治疗前及治疗后6个月分别测血清胰岛素样生长因子-Ⅰ (IGF-Ⅰ)和NTproCNP的浓度.治疗1年后,计算所有患儿的GV、身高Z积分(HTSDS)以及身高Z积分的变化值(△HTSDS).结果 IGHD组中,治疗前后IGF-I Z积分的变化值(△IGF-ISDS)、NTproCNP浓度的变化值(△NTproCNP)与治疗1年中GV呈正相关(r=0.407,P=0.044;r=0.490,P=0.013);治疗前生长激素(CH)峰值也与治疗前IGF-ISDS、NTproCNP浓度(r=0.558,P=0.004;r=0.630,P=0.001)以及治疗后△IGF-ISDS与△NTproCNP呈正相关(r=0.466,P=0.019).而在ISS患儿中,治疗1年中GV只与治疗后△NTproCNP相关(r=0.845,P<0.01).结论 在IGHD和ISS患儿应用rhGH的促生长治疗中,NTproCNP水平随着生长速率的增加而增加.因此除了IGF-I,NTproCNP作为一种新的生化标记物,也可用于评估和预测这两类患儿在rhGH治疗后的GV变化. 相似文献
5.
重组人生长激素治疗慢性阻塞性肺疾病营养不良安全性研究进展 总被引:3,自引:0,他引:3
慢性阻塞性肺疾病(chronic obstructive pulmonary disease,COPD)患者大多并发营养不良,其原因众多;而营养不良是判断COPD患者预后一项独立的影响因素,因此改善COPD患者的营养状况尤其重要。重组人生长激素(recombinant human growth hormone,rhGH)能促进蛋白质的合成、脂肪及糖合理利用、增加呼吸肌收缩力、改善COPD患者的营养状态,但临床应用中也存在一些不良反应,故对rhGH治疗COPD营养不良的安全性进行研究,可为改善COPD患者的营养状况提供理论依据。 相似文献
6.
Ghrelin对心血管系统作用的研究进展 总被引:2,自引:0,他引:2
Ghrelin 是生长激素促分泌素受体(growth hormonese secretagogue receptor,GHSR)的内源性配体,最早由 Koima 等从大鼠胃粘膜细胞分离,纯化而得。Ghrelin 能有效促进生长激素(growth hormone,GH)分泌,调节进食、能量平衡,还对心血管系统发挥重要作用。 相似文献
7.
《中国实用内科杂志》2017,(10)
正成人生长激素缺乏症(adult growth hormone deficiency,AGHD)是指成人期由于缺乏生长激素(growth hormone,GH)所引起的相关临床症状及相应生化改变,常继发于各种颅脑损伤,少部分患者为特发性。特发性AGHD临床表现隐匿、缺乏特异性,易被漏诊、误诊。GH能拮抗肌肉和肝脏中胰岛素对葡萄糖的摄取和利用,引起胰岛素抵抗并提高脂 相似文献
8.
Effects of recombinant human growth hormone on growth of human gastric carcinoma xenograft model in nude mice 总被引:1,自引:0,他引:1
Liang DM Chen JY Zhang Y Gan P Lin J Chen AB 《World journal of gastroenterology : WJG》2006,12(24):3810-3813
AIM: To study effects of recombinant human growth hormone (rhGH) on growth of a human gastric carcinoma cell in vivo. METHODS: Experimental mice were divided into control group, rhGH group, oxaliplatin (L-OHP) group and rhGH L-OHP group. Cultured human gastric carcinoma cells BGC823 were inoculated into right axilla of nude mice and carcinoma xenograft model was established successfully. Inhibitory rate of xenograft tumor growth was estimated by measuring tumor volume; expression of proliferating cell nuclear antigen (PCNA), Bax and Bcl-2 proteins of xenograft tumor was detected using immunohistochemical S-P method. RESULTS: Tumor growth inhibitory rate, the positive expression rate of PCNA, Bax and Bcl-2 were 49.3%, 58.2%, 65.2% and 59.2% in rhGH L-OHP group respectively; 46.6%, 62.5%, 59.7% and 64.7% in L-OHP group; 5.0%, 82.7%, 23.2% and 82.2% in rhGH group and 0, 77.8%, 23.5% and 80.3% in control group. There was significant difference between rhGH L-OHP group (or L-OHP group ) and control group or rhGH group (P < 0.05), whereas there were no significant differences (P > 0.05) between L-OHP group and rhGH L-OHP group and between rhGH group and control group. CONCLUSION: rhGH does not accelerate the proliferation of human gastric cancer cell in vivo. 相似文献
9.
10.
生长素的心血管调节作用 总被引:1,自引:1,他引:1
生长素(Ghrelin)是1999年日本科学家Kojima等[1]在小鼠和人胃内分泌细胞及下丘脑弓状核中发现的含有28个氨基酸残基的多肽,是生长激素促分泌素受体(growth hormone secretatogue receptor,GHS-R)的内源性配体,能够刺激垂体前叶释放生长激素(growth hormone,GH).GHS-R不仅存在于下丘脑、垂体等部位,在心血管系统包括心脏、冠状动脉、主动脉等部位亦广泛存在,而且心脏本身也合成和分泌生长素,因此,生长素也可能作为一个旁/自分泌因子参与心血管稳态调节. 相似文献
11.
12.
以重组人生长激素(rhGH)治疗12例青春发育后期女孩(年龄11~13岁)6个月,每日0.10~0.12IU/kg rhGH治疗提高了他们的身高生长。 相似文献
13.
14.
基因重组生长激素对大鼠肝细胞生长激素受体表达及血清蛋白的影响 总被引:4,自引:0,他引:4
研究发现,肾病综合征(NS)患者体内胰岛素样生长因子-1(IGF-1)浓度降低,但其生长激素(GH)浓度正常[1],可能是生长激素受体(growth hormone receptor,GHR)表达下降导致GH生物效应受到抑制,机体IGF-1合成及分泌减少,使GH/IGF-1轴强大的合成功能受限,加重了NS患者的低蛋白血症. 相似文献
15.
恶性肿瘤病人往往伴有营养不良,术后应用人重组生长激素(rhGH)能明显增加蛋白合成,改善机体免疫功能、降低应激反应以及减少并发症的发生,因而已逐渐在外科术后病人中广泛使用。但是,由于术后体内肿瘤细胞的残留不可避免,使用rhGH是否会刺激肿瘤细胞生长?围手术期使用是否安全?目前学术界尚无共识。由于rhGH作用于细胞生长激素受体(GHR)来发挥作用,所以现将GHR在肿瘤组织中的表达情况以GH—GHR—IGFs轴与肿瘤的关系的有关研究综述加下. 相似文献
16.
Ghrelin是促生长激素分泌素受体(growth hormone secretagogue receptor,GHSR)的内源性配体,主要由胃X/A样细胞分泌。 相似文献
17.
目的 比较分析单纯促性腺激素释放激素类似物(GnRHa)或联合重组人生长激素(rhGH)治疗青春期非生长激素缺乏矮小(NGHDSS)患儿的助长疗效,探讨科学有效的青春期助长治疗方案.方法 42例青春期NGHDSS患儿(男性14,女性28),采用GnRHa联合rhGH治疗者(联合组)30例,单独GnRHa 治疗者(单治组)12例.GnRHa初始剂量100ug·kg-1·d-1(28 d),维持剂量60-80μg·kg-1·d-1(28d);rhGH初始剂量0.15 IU·ks-1·d-1(28 d),维持剂量0.10~0.15 IU·ks-1·d-1(28 d),疗程均为1-2年.主要观察各组年生长速率(GV)、对年龄的身高标准差分值(HtSDSCA)、对骨龄的身高标准差分值(HtSDSBA)、预测身高标准差分值(PAHSDS)的动态变化.结果 (1)1年疗效:联合组治疗前后比较,GV、HtSDSCA、HtSDSBA、PAHSDS变化均有统计学意义(均P<0.05).单治组患儿治疗前后比较,GV、HtSDSCA、HtSDSBA、PAHSDS变化均无统计学意义(均P>0.05).2组间比较,GV、HtSDSBA、PAHSDS均有显著性差异(均P<0.05).(2)2年疗效:联合组治疗前后比较,GV、HtSDSCA、HtSDSBA、PAHSDS变化均有统计学意义(均P<0.05).单治组治疗前后比较,GV、HtSDSCA、HtSDSBA、PAHSDS变化均无统计学意义(均P>0.05).2组间比较,GV、HtSDSBA、HtSDSCA、PAHSDS均有显著性差异(均P<0.05).结论 采用GnRHa联合rhGH治疗青春发育初期的NGHDSS患儿能有效促进近期生长速率,其疗效明显优于单独GnRHa治疗,但对成年终身的贡献尚待研究.Abstract: Objective To assess the efficacy of gonadotropin-releasing hormone analogue(GnRHa)with or without recombinant human growth hormone(rhGH)treatment in Chinese short pubertal children with non-growth hormone deficiency.Methods Of 42 short pubertal children(14 males,28 females)without growth hormone deftcieney,the average age was(11.6±0.8)year.30 children were treated with slow release GnRHa with initial dose (100μg·kg-1·d-1,28d)and maintenance dose(60-80μg·kg-1·d-1,28d)labd rgGH with initial dose(0.15IU·kg-1·d-1)and maintenance dose(0.10-0.15IU·kg-1·d-1)for at least 1year.16 of them were still ongoing till the end of the second year.12 children were treated with GnRHa alone by initial dose(100μg·kg-1·d-1,28d)and maintenance dose (60-80μg·kg-1·d-1,28d),and 7 of them remained on it for 2 years.Dynamic changes including annual growth velocity(GV),bone age(BA)/chronologic age(CA)ratio,Tanner stage,height SDS for CA (HtSDSCA),height SDS for BA(HtSDSBA),and predicted adult height (PAHSDS)were observed.Results By the end of the first year tretment with combination therapy,the following parameters:GV,HtSDSCA,HtSDSBA,and PAHSDS all increased significantly(all P<0.05).Treatment with GnRHa alone did not yield significant changes in GV,HtSDSCA,HtSDSBA,and PAHSDS(all P>0.05).Changes in GV,HtSDSBA,and PAHSDS between these two groups were statistically significant(all P<0.05).By the end of the second year treatment,in the combination group,GV slowed from 6.7 to 5.5 cm/year(P<0.05).HtSDSCA,HtSDSBA,PAHSDS increased(all P<0.05).In the group with GnRHa treatment alone,GV slowed from 4.0 to 3.6 cm/year(P>0.05).HtSDSCA,HtSDSBA,PAHSDS increased(all P>0.05).Changes in GV,HtSDSCA,HtSDSBA,and PAHSDS between these 2 groups were statistically significant respectively(all P<0.05).Conclusion This combined treatment regimen significantly impreved the growth by increasing growth rate and delaying bone matumtion in pubertal chidren without growth hormone deficiency.Further study is needed to verify beneficial effects on the final height gain. 相似文献
18.
目的 观察重组人生长激素(rhGH)对于促性腺激素释放激素类似物(GnRHa)治疗中生长过度减速的特发性中枢性性早熟(ICPP)女孩的最终成年身高(FAH)的影响.方法 49例ICPP女孩接受GnRHa治疗,当身高增长速度减慢至4 cm/年以下时,其中26例联用rhGH治疗为联合治疗组,23例拒绝加用rhGH但继续使用GnRHa为单用组.比较2组治疗前后的预测成年身高(PAH)和FAH.结果 联合治疗组联用rhGH前半年,身高增长速度均小于4 cm/年[(3.2±1.0)cm/年],PAH无明显改善[联用rhGH前半年和rhGH开始时PAH分别为(152.5±4.0)cm和(152.6±3.7)cm];联用rhGH(11.4±5.4)个月后,身高增长速度增加至(6.7±2.0)cm/年,PAH增加至治疗结束时的(157.1±4.7)cm(均P<0.01);FAH[(157.5±4.5)cm]显著高于GnRHa开始时的PAH[(148.1±4.6)cm]和遗传靶身高[(154.4±4.6)cm,均P<0.01].单用组治疗结束时的PAH[(153.9±6.3)cm]较拒绝联用rhGH时的PAH[(153.1±6.2)cm]无差异;FAH[(154.7±5.5)cm]高于治疗开始时的PAH[(150.3±6.0)cm,P<0.01],但与遗传靶身高[(155.6±4.3)cm]无差异.结论 联用rhGH能够显著加快GnRHa治疗中生长过度减速的ICPP女孩的身高增长速度,进一步改善PAH和FAH.Abstract: Objective To evaluate the long-term final adult height outcome of combined treatment with gonadotropin-releasing hormone analogue(GnRHa)and recombinant human growth hormone(rhGH)in girls with idiopathic central precocious puberty(ICPP).Methods Out of 49 sirls with ICPP[treated with GnRHa at a dose of 60-80 μg/kg every 4 weeks for at least 6 months,whose height velocity fell below 4 cm/year and showed no improvement of predicted adult height(PAH)in 6 months],26 received(rhGH-combined group),in addition to chronological age,and duration of GnRHa treatment,who showed the same growth pattern but refused rhGH treatment,served to evaluate the efficacy of rhGH in addition.At the conclusion of the smdy,all the girls had been followed up for(3.3±1.9)years,and(3.2±0.9)years in rhGH-combined group and control group,respectively;and had achieved adult heisht.To compare the PAH with the final adult height(FAH)before and after treatment in the two groups.Results During rhGH treatment, height velocity of the rhGH-combined girls increased significantly[(6.7±2.0 vs <4)cm/year baseline],RhGH-combined gids showed an adult height far higher than pretreatment PAH [(157.5±4.5 vs 148.1±4.6)cm,P<0.01],and target height[(154.4±4.6)cm] was,significantly excceded.The control group reached an adult heisht also significandy higher than pretreatment PAH[(154.7±5.5vs 150.3±6.0)cm,P<0.01],while target height[(155.6±4.3)cm]was just reached but not significantlyexcceded.The gain in height obtained,calculated between pretreatment PAH and final heisat,(9.4±4.9)cm in rhGH-combined group was much more than that(4.3±4.2)cm in the control group(P<0.01).Conclusion RhGH may accelerate the linear growth and improve adult height of GnRHa-treated ICPP girls. 相似文献
19.
谢文鹏 《国际内分泌代谢杂志》1987,(1)
在下丘脑激素中,LHRH、TRH负荷试验已在日常临床检查中占有重要位置。最近,已搞清了它们的化学结构 已合成的促肾上腺皮质释放因子(Corticotropin releasing factor,简称CRF)和生长激素释放因子(growth hormone relea-sing factor简称GRF)的临床应用颇受重视。 1、CRF负荷试验 相似文献
20.
生长激素(growth hormone,GH)是腺垂体合成和分泌的重要激素之一,大部分通过其介质胰岛素样生长因子-1(insu lin-like growth factors-1,IGF-1)发挥作用。GH/IGF-1对心血管系统具有促进心肌生长,增强心肌收缩力等特殊效应。因而在心力衰竭的治疗中有着重要的价值,现对GH/IGF-1治疗心力衰竭的可能机制作一综述。 相似文献